Beijing Beilu Pharmaceutical (300016) - Total Liabilities
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has total liabilities worth CN¥852.80 Million CNY (≈ $124.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beijing Beilu Pharmaceutical - Total Liabilities Trend (2005–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. See Beijing Beilu Pharmaceutical (300016) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Beijing Beilu Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ECN Capital Corp
TO:ECN
|
Canada | CA$757.90 Million |
|
Stingray Group Inc
TO:RAY-A
|
Canada | CA$866.47 Million |
|
Shenzhen SDG Service Co. Ltd.
SHE:300917
|
China | CN¥736.15 Million |
|
Wereldhav B-Sicafi
BR:WEHB
|
Belgium | €460.95 Million |
|
Grenke AG
XETRA:GLJ
|
Germany | €7.40 Billion |
|
Südwestdeutsche Salzwerke AG
F:SSH
|
Germany | €268.72 Million |
|
China Oil HBP Science & Technology Co Ltd
SHE:002554
|
China | CN¥3.61 Billion |
|
Zhong Fu Tong Co Ltd
SHE:300560
|
China | CN¥1.64 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Beijing Beilu Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Beijing Beilu Pharmaceutical market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Beilu Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual total liabilities of Beijing Beilu Pharmaceutical from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.15 Billion ≈ $167.99 Million |
+11.12% |
| 2023-12-31 | CN¥1.03 Billion ≈ $151.18 Million |
+15.78% |
| 2022-12-31 | CN¥892.27 Million ≈ $130.57 Million |
+9.05% |
| 2021-12-31 | CN¥818.22 Million ≈ $119.73 Million |
-14.37% |
| 2020-12-31 | CN¥955.50 Million ≈ $139.82 Million |
+451.32% |
| 2019-12-31 | CN¥173.31 Million ≈ $25.36 Million |
+108.99% |
| 2018-12-31 | CN¥82.93 Million ≈ $12.13 Million |
+15.74% |
| 2017-12-31 | CN¥71.65 Million ≈ $10.48 Million |
+31.71% |
| 2016-12-31 | CN¥54.40 Million ≈ $7.96 Million |
-53.66% |
| 2015-12-31 | CN¥117.39 Million ≈ $17.18 Million |
-51.22% |
| 2014-12-31 | CN¥240.67 Million ≈ $35.22 Million |
+293.50% |
| 2013-12-31 | CN¥61.16 Million ≈ $8.95 Million |
+2.56% |
| 2012-12-31 | CN¥59.64 Million ≈ $8.73 Million |
+79.71% |
| 2011-12-31 | CN¥33.19 Million ≈ $4.86 Million |
+343.20% |
| 2010-12-31 | CN¥7.49 Million ≈ $1.10 Million |
-57.46% |
| 2009-12-31 | CN¥17.60 Million ≈ $2.58 Million |
-33.62% |
| 2008-12-31 | CN¥26.52 Million ≈ $3.88 Million |
-48.36% |
| 2007-12-31 | CN¥51.36 Million ≈ $7.52 Million |
-5.07% |
| 2006-12-31 | CN¥54.10 Million ≈ $7.92 Million |
+26.55% |
| 2005-12-31 | CN¥42.75 Million ≈ $6.26 Million |
-- |
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more